🔴 Definium Therapeutics is trading 4.04% down; catalyst remains unclear

Definium Therapeutics is trading 4.04% down at $35.41, with no confirmed company-specific catalyst identified.

• Shares closed at $36.90, up 7.96%, on October 9.
• No confirmed October 12 company-specific announcement explaining the decline was found. The October 9 JPMorgan upgrade was positive, not a clear explanation.
• Major indices are nearly flat, so broad-market weakness is not an evident driver.